Geno SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Geno SA - overview
Established
1935
Location
-, -, Norway
Primary Industry
Agribusiness
About
Based in Norway, Geno SA specializes in the development of genetic products for livestock, particularly focusing on improving dairy cattle breeding through advanced genetic solutions. Established in 1935 in Norway, Geno SA is dedicated to enhancing livestock breeding practices. The company has evolved its offerings over the years but maintains its core focus on genetic improvements in cattle. Its operations are centralized in Norway, with a network that extends across Europe.
The organization is led by a team of experienced professionals committed to advancing their sector. Geno specializes in the development and provision of genetic products and services aimed at enhancing livestock breeding, specifically for dairy cattle. Its core offerings include the distribution of bovine semen and embryos from Norwegian Red Cattle (NRF), which are tailored for improved fertility, productivity, and overall animal health. Geno provides a range of related educational resources through digital platforms, including online courses and podcasts that focus on breeding techniques, animal fertility, and industry insights.
These products and services are primarily aimed at farmers, agricultural producers, and livestock breeders across Norway and other European markets, where they address the need for genetic improvements in cattle to achieve higher efficiency and profitability in dairy production. In 2023, Geno reported a revenue of USD 15. 67 mn and an EBITDA of USD 2. 01 mn.
The company operates on a transaction-based revenue model, primarily through the sale of genetic materials such as semen and embryos. Clients, which include dairy farmers and agricultural businesses, engage in direct purchases or subscriptions for these genetic products. Transactions typically involve bulk orders or regular supply agreements that ensure a consistent flow of genetic resources to clients, thereby facilitating sustainable farming practices. The flagship products, particularly the genetically superior NRF semen, serve as a cornerstone of Geno’s revenue stream, reinforcing their commitment to advancing livestock breeding and agricultural sustainability.
Looking to the future, Geno plans to expand its product line with new genetic solutions aimed at enhancing the efficiency of dairy production. The company is targeting growth in new geographical markets, particularly in other European nations, by 2025. Recent funding will be allocated towards research and development efforts to innovate their product offerings and enhance their market reach.
Primary Industry
Agribusiness
Sub Industries
Consulting Services, Education & Training Website, Farm Support Services
Website
www.geno.no
Verticals
E-commerce, EdTech, Research (Non-Medical)
Total Amount Raised
Subscriber access only
Geno SA - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 118,534,000 | 120,358,000 | 131,742,000 | 319,868,397 | - | 331,943,849 | 183,922,969 | 189,009,299 | 147,083,434 | - | - | - |
| % Revenue Growth (YoY) | - | 1.5% | 9.5% | 142.8% | - | - | (44.6%) | 2.8% | (22.2%) | - | - | - |
| EBITDA (USD) | 6,308,000 | 7,932,000 | 27,906,000 | 25,904,042 | - | 17,910,506 | 26,553,443 | 63,597,184 | 4,004,215 | - | - | - |
| Operating Income (USD) | (3,770,000) | (3,490,000) | 13,453,000 | 10,967,042 | - | 1,552,506 | 6,352,443 | 42,857,841 | (9,605,785) | - | - | - |
| Operating Margin | (3.2%) | (2.9%) | 10.2% | 3.4% | - | 0.5% | 3.5% | 22.7% | (6.5%) | - | - | - |
| % EBITDA Margin | 5.3% | 6.6% | 21.2% | 8.1% | - | 5.4% | 14.4% | 33.6% | 2.7% | - | - | - |
| NET Income (USD) | (3,924,000) | (4,805,000) | 9,728,000 | (1,672,688) | - | 802,299 | 6,222,614 | 41,941,093 | (9,131,114) | - | - | - |
| % Net Margin | (3.3%) | (4.0%) | 7.4% | (0.5%) | - | 0.2% | 3.4% | 22.2% | (6.2%) | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.